MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts compl

Social Author Image
https://pbs.twimg.com/profile_images/1322922848810422289/oM4qP9_k_normal.jpg
Tweet Author
ericdeinmd
Social Author Name
Eric Dein
Tweet Content
MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu
Links
https://x.com/ericdeinmd/status/1857773289474507223/photo/1
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×